No new information was released — the reaffirmation simply reiterates existing targets. Monitor upcoming quarterly filings for any deviation from the reaffirmed guidance range, particularly around medical cost trends reflected in the 90.2% benefit expense ratio.
Price Chart
Executive Summary
Elevance Health filed an 8-K to publicly reaffirm its full-year 2026 guidance during investor meetings this week. The company confirmed adjusted EPS of at least $26.75 (and GAAP EPS of at least $19.85) and a benefit expense ratio of 90.2% ±50bps. This is a routine FD disclosure with no new financial data or revisions, merely a reiteration of previously stated targets.
Key Facts
- Management reaffirmed full-year 2026 GAAP EPS of at least $19.85 per share, including ~$6.90/share of net unfavorable items.
- Adjusted (non-GAAP) EPS reaffirmed at at least $26.75 per share.
- Full-year 2026 benefit expense ratio guidance reaffirmed at 90.2% plus or minus 50 basis points.
- Guidance does not include any adjustment items beyond those reported in Q1 2026 earnings.
- Filing is a Regulation FD disclosure of investor meeting talking points; no change to prior guidance.
Financial Impact
No financial figures were changed or revised. Reaffirmation of existing guidance at the same levels as previously communicated.
Risk Factors
- Medical cost trends could deviate from the 90.2% guidance band, pressuring margins.
- Macroeconomic or regulatory changes could impact enrollment and premium adequacy.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001156039-26-000049 |
| Document: 0001156039-26-000049-index-headers.html | 0001156039-26-000049 |
| Document: 0001156039-26-000049-index.html | 0001156039-26-000049 |
| Document: 0001156039-26-000049.txt | 0001156039-26-000049 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $416.54 $414.26 | ▼ −0.55% | ▼ −0.05% | $381.34 (−8.45%) |
Aug 27, 2026 5w ago | Institutional Cluster | $399.11 $414.78 | ▲ +3.93% | ▲ +3.66% | $381.34 (−4.45%) |
Aug 20, 2026 6w ago | Court Ruling | $396.28 $399.11 | ▲ +0.71% | ▼ −0.40% | $381.34 (−3.77%) |
Aug 17, 2026 6w ago | Court Ruling | $390.24 $402.63 | ▲ +3.17% | ▲ +4.37% | $381.34 (−2.28%) |
Jul 17, 2026 10w ago | Insider Cluster | $373.11 $379.31 | ▲ +1.66% | ▲ +2.35% | $381.34 (+2.21%) |
Jul 15, 2026 11w ago | 8-K | $390.33 $389.09 | ▼ −0.32% | ▲ +0.66% | $381.34 (−2.30%) |
Jun 15, 2026 15w ago | Insider Cluster | $397.80 $395.10 | ▼ −0.68% | ▲ +1.55% | $381.34 (−4.14%) |
Jun 10, 2026 16w ago | 8-K | $404.56 $397.80 | ▼ −1.67% | ▼ −5.10% | $381.34 (−5.74%) |
Apr 22, 2026 23w ago | 8-K | $328.20 $368.75 | ▼ −12.36% | ▼ −12.30% | $381.34 (−16.19%) |
Mar 27, 2026 26w ago | DEFA14A | $284.79 $311.83 | ▲ +9.49% | ▲ +5.19% | $381.34 (+33.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access